XLR-11 (5"-fluoro-UR-144 or 5F-UR-144) is a drug that acts as a potent agonist for the cannabinoid receptors CB1 and CB2 with EC50 values of 98 nM and 83 nM, respectively.[2] It is a 3-(tetramethylcyclopropylmethanoyl)indole derivative related to compounds such as UR-144, A-796,260 and A-834,735, but it is not specifically listed in the patent or scientific literature alongside these other similar compounds,[3][4] and appears to have not previously been made by Abbott Laboratories, despite falling within the claims of patent WO 2006/069196. XLR-11 was found to produce rapid, short-lived hypothermic effects in rats at doses of 3 mg/kg and 10 mg/kg, suggesting that it is of comparable potency to APICA and STS-135.[2]
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C21H28FNO |
Molar mass | 329.459 g·mol−1 |
3D model (JSmol) |
|
| |
|
A forensic standard for this compound is available, and a representative mass spectrum has been posted on Forendex.[5]
XLR-11 was instead first identified by laboratories in 2012 as an ingredient in synthetic cannabis smoking blends, and appears to be a novel compound invented specifically for grey-market recreational use.[6]
XLR-11 was banned in New Zealand by being added to the temporary class drug schedule, effective from 13 July 2012.[7]
The U.S. Drug Enforcement Administration (DEA) made XLR11 illegal under the Federal Controlled Substances act for the foreseeable future as of January 2024.[8]
It has also been banned in Florida as of 11 December 2012.[9]
Arizona banned XLR-11 on 3 April 2013.[10]
As of October 2015 XLR-11 is a controlled substance in China.[11]
XLR-11 is banned in the Czech Republic.[12]
XLR-11 has been linked to hospitalizations due to its use.[13]
XLR-11 has been linked to acute kidney injury in some users,[14] along with AM-2201.[15][16]
{{cite web}}
: Missing or empty |title=
(help)